Menninger H, Reinhardt S, Söndgen W
I. Med. Klinik, BRK Rheuma-Zentrum, Bad Abbach, Germany.
Scand J Rheumatol. 1994;23(5):249-54. doi: 10.3109/03009749409103724.
Thirty-one patients with knee effusions associated with rheumatoid arthritis (RA) have been treated with two intraarticular (i.a.) injections of each 330 mg sodium morrhuate (SM) used for synoviorthesis versus a single injection of 20 mg triamcinolone hexacetonide (TA). During an observation period of one year, five articular parameters as well as patient's and doctor's global assessments were evaluated. TA showed an earlier onset and a longer duration of therapeutic effects with high statistical significance. The maximum improvement was significantly more pronounced with TA than with SM. Finally after one year improvement measured by a remission index was observed in 81% versus 33% resp. of all joints injected. Due to ineffectiveness of the primary treatment nine patients (60%) out of the SM group, but not patient out of the TA group had to be crossed over to the other treatment. SM usually caused a reactive effusion within hours after injection requiring arthrocentesis. In conclusion efficacy and tolerability are clearly better for TA than for SM.
31例类风湿关节炎（RA）伴膝关节积液患者接受了用于滑膜切除术的330mg鱼肝油酸钠（SM）关节内（i.a.）注射两次，与单次注射20mg曲安奈德（TA）进行对比。在一年的观察期内，评估了五个关节参数以及患者和医生的整体评估。TA显示出起效更早且治疗效果持续时间更长，具有高度统计学意义。TA的最大改善明显比SM更显著。最后，一年后通过缓解指数测量，分别在81%和33%的注射关节中观察到改善。由于初始治疗无效，SM组中有9名患者（60%）不得不改用另一种治疗，但TA组中没有患者需要更换。SM通常在注射后数小时内引起反应性积液，需要进行关节穿刺。总之，TA的疗效和耐受性明显优于SM。
